Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

Abstract Background While immune checkpoint inhibitor (ICI) therapies can significantly improve outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC), only about 15–20% benefit from such treatments. Clinical tests that guide the use of ICIs are therefore cr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey Hiken, Jon Earls, Kevin C. Flanagan, Rachel L. Wellinghoff, Michelle Ponder, David N. Messina, Jarret I. Glasscock, Eric J. Duncavage
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
OncoPrism
Head and neck cancer
HNSCC
Analytical validation
Biomarker
Classifier
Online Access:https://doi.org/10.1186/s12885-024-13362-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13362-8

Similar Items